Orphan drug legislation: Lessons for neglected tropical diseases

International Journal of Health Planning and Management

Volumn 24, Issue 1, 2009, Pages 27-42

  Villa, Stefano ^a   Compagni, Amelia ^a   Reich, Michael R ^b  

^a BOCCONI UNIVERSITY   (Italy)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Orphan drug; Orphan drug legislation rare diseases; Tropical diseases

Indexed keywords

AGALSIDASE BETA; BCG VACCINE; DORNASE ALFA; EFLORNITHINE; ERYTHROPOIETIN; HALOFANTRINE; IMATINIB; IMIGLUCERASE; JAPANESE ENCEPHALITIS VACCINE; LARONIDASE; MEFLOQUINE; ORPHAN DRUG; PAROMOMYCIN; PENTAMIDINE ISETHIONATE;

DEVELOPING WORLD; DISEASE TREATMENT; DRUG; LEGISLATION; MEDICINE; ORPHAN; RESEARCH AND DEVELOPMENT;

AFRICAN TRYPANOSOMIASIS; ANEMIA; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CYSTIC FIBROSIS; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EUROPEAN UNION; FABRY DISEASE; GAUCHER DISEASE; GOVERNMENT REGULATION; HUMAN; HURLER SYNDROME; INVESTMENT; JAPAN; MALARIA; PATENT; PREVALENCE; PRODUCT DEVELOPMENT; RARE DISEASE; REIMBURSEMENT; TROPICAL DISEASE; TRYPANOSOMIASIS; UNITED STATES; VIRUS ENCEPHALITIS; VISCERAL LEISHMANIASIS; DRUG MANUFACTURE; INTERNATIONAL COOPERATION; LEGAL ASPECT; NONBIOLOGICAL MODEL; RESEARCH; TROPICAL MEDICINE;

DRUG INDUSTRY; HUMANS; INTERNATIONAL COOPERATION; MODELS, ORGANIZATIONAL; ORPHAN DRUG PRODUCTION; RARE DISEASES; RESEARCH; TROPICAL MEDICINE;

EID: 65549112639     PISSN: 07496753     EISSN: 10991751     Source Type: Journal    
DOI: 10.1002/hpm.930     Document Type: Article

References (39)

1. Abbott FM. 2002. The DOHA declaration on the TRIPS agreement and public health: lighting a dark corner at the WT. J Int Econ Law 5(2): 469-505.
2. Alcimed. 2005. Study on orphan drugs. Considerations on the application of Article 8.2 of EC Regulation no. 141/2000 concerning orphan drugs. http://pharmacos.eudra.org/F2/orphanmp/doc/pricestudy/ Final%20final%20report%20part%202%20web.pdf2005 (last accessed 28 January 2008).
3. Arno P, Bonuk K, Davis M. 1995. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act. Milbank Q 73(2): 231-252.
4. Berndt ER, Hurvitz JA. 2005a. Vaccine advance-purchase agreements for low-income countries: practical issues. Health Aff 24(3): 653-665.
5. Berndt ER, Gottschalk AHB, Philipson TJ, Strobeck MW. 2005b. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov 4(7): 545-554.
6. Borgman RJ. 1992. Development of an orphan drug by a start-up company. Int J Technol Assess Health Care 8(4): 566-572.
7. Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K. 2006. Translating Epoetin research into Practice: the role of government and the use of scientific evidence. Health Aff 25(5): 1249-1259.
8. Datamonitor. 2006. PharmaVitae: Genzyme Corporation (ref CSHC1314). London.
9. DiMasi J. 1995. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 58(1): 1-14.
10. Gastellu Etchegorry M, Helenport JP, Pecoul B, Jannin J, Legros D. 2001. Avaliability and affordability of treatment for Human African Trypanosomiasis. Trop Med Int Health 6(11): 957-959.
11. GlaxoSmithKline. 2001. Facing the challenge. http://www.gsk.com/ responsibility/Downloads/how_to_access.pdf (last accessed 1 August 2006).
12. Goldman DP, Clarke AE, Garber AM. 1992. Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase. Int J Technol Asses Health Care 8(4): 583-597.
13. Grabowski H, Vernon J. 2000. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 18 (Suppl 1): 21-32.
14. Haffner ME. 1996. Orphan drug development update. Drug Inf J 30: 29-34.
15. Haffner ME, Whitley J, Moses M. 2002. Two decades of orphan product development. Nat Rev Drug Discov 1(10): 821-825.
16. Haffner ME. 2006. Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med 354(5): 445-447.
17. Hale VG, Woo K, Lipton HL. 2005. Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world. Health Aff 24(4): 1057-1063.
18. Kettler HE, Madanovic S. 2004. Engaging biotechnology companies in the development of innovative solutions for diseases of poverty. Nat Rev Drug Discov 3: 171-176.
19. Kumar P, Zaugg A-M. 2003. IMS Review: steady but not stellar. In IMS Health. Business Watch. http://www.imshealth.com/vgn/images/portal/ cit_40000873/42912029Business%20Watch.pdf (last accessed 15 January 2007).
20. Joppi R, Bertele V, Garattini S. 2006. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 61(3): 355-360.
21. Kremer M. 2002. Pharmaceuticals and the developing world. J Eco Perspect 16(4): 67-90.
22. Kremer M, Glennerster R. 2004. Strong Medicine. Princeton University Press: Princeton and Oxford.
23. Lang T, Hill AV, McShane H, et al. 2005. New TB vaccine granted orphan drug status. BMJ 331(7530): 1476.
24. Moorthy VS, Good MF, Hill AV. 2004. Malaria vaccine developments. Lancet 363(9403): 150-156.
25. Moukheiber Z. 2003. Protecting the orphan drugs. http://www.forbes.com/ 2003/09/12/cz_zm_0910oneworld.html (last accessed 15 January 2007).
26. Medicins Sans Frontieres. 2006. Background: Novartis files case in India challenging patent office order and patent law. Cancer patients demand withdrawal of cases. http://www. accessmed-msf.org/prod/ publications.asp?scntid=26920061034109&contenttype=PARA& (last accessed 15 January 2007).
27. Olson MK. 2004. Are novel drugs more risky for patients than less novel drugs? J Health Econ 23(6): 1135-1158.
28. Pécoul B, Chirac P, Trouiller P, Pinel J. 1999. Access to essential drugs in poor countries. A lost battle? JAMA 281(4): 361-367.
29. Peters DH, Phillips T. 2004. Mectizan Donation Program: evaluation of a public-private partnership. Trop Med Int Health 9(4): A4-A15.
30. Pisano GP. 2006. Science Business. Harvard Business School Press: Cambridge.
31. Reich M. 2000. The global drug gap. Science 287(5460): 1979-1981.
32. Rhode D. 2000. The Orphan Drug Act: an engine of innovation? At what cost? Food Drug Law J 25(1): 125-144.
33. Ridley DB, Grabowski HG, Moe JL. 2006. Developing drugs for developing countries. Health Aff 25(2): 313-324.
34. Robbins-Roth C. 2000. From Alchemy to IPO: The Business of Biotechnology. Perseus Publishing: Cambridge.
35. Sheridan C. 2004. EU to review rare disease drugs market exclusivity. Nat Biotechnol 22: 1061.
36. Shulman SR, Bienz-Tadmor B, Seo PS, DiMasi JA, Lasagna L. 1942. Implementation of the Orphan Drug Act. Food Drug Law J 47: 363-403.
37. Trouiller P, Battistella C, Pinel J, Pecoul B. 1999. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts. Trop Med Int Health 4(6): 412-420.
38. Trouiller P, Olliaro P, Toreele E, Orbinski J, Laing R, Ford N. 2002. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359(9324): 2188-2194.
39. World Health Organization. Commission on Intellectual Property Rights, Innovation and Public Health. 2006. Public health, innovation and intellectual property rights: report of the Commission on Intellectual Property Rights, Innovation and Public Health. http://www.who.int/ intellectualproperty/documents/thereport/ENPublicHealthReport.pdf (last accessed 28 January 2008).